AU2007275535B2 - Recombinant host for producing L-asparaginase II - Google Patents

Recombinant host for producing L-asparaginase II Download PDF

Info

Publication number
AU2007275535B2
AU2007275535B2 AU2007275535A AU2007275535A AU2007275535B2 AU 2007275535 B2 AU2007275535 B2 AU 2007275535B2 AU 2007275535 A AU2007275535 A AU 2007275535A AU 2007275535 A AU2007275535 A AU 2007275535A AU 2007275535 B2 AU2007275535 B2 AU 2007275535B2
Authority
AU
Australia
Prior art keywords
asparaginase
enzyme
host cell
recombinant
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2007275535A
Other languages
English (en)
Other versions
AU2007275535A1 (en
Inventor
David R. Filpula
Maoliang Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Servier IP UK Ltd
Original Assignee
Servier IP UK Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Servier IP UK Ltd filed Critical Servier IP UK Ltd
Publication of AU2007275535A1 publication Critical patent/AU2007275535A1/en
Assigned to DEFIANTE FARMACEUTICA, S.A. reassignment DEFIANTE FARMACEUTICA, S.A. Request for Assignment Assignors: ENZON PHARMACEUTICALS, INC.
Assigned to SIGMA-TAU RARE DISEASES, S. A. reassignment SIGMA-TAU RARE DISEASES, S. A. Request for Assignment Assignors: DEFIANTE FARMACEUTICA, S.A.
Application granted granted Critical
Publication of AU2007275535B2 publication Critical patent/AU2007275535B2/en
Assigned to SIGMA-TAU PHARMA LIMITED reassignment SIGMA-TAU PHARMA LIMITED Request to Amend Deed and Register Assignors: SIGMA-TAU RARE DISEASES, S. A.
Assigned to Servier IP UK Limited reassignment Servier IP UK Limited Request to Amend Deed and Register Assignors: SIGMA-TAU PHARMA LIMITED
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C12N9/80—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in linear amides (3.5.1)
    • C12N9/82—Asparaginase (3.5.1.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2007275535A 2006-06-30 2007-06-08 Recombinant host for producing L-asparaginase II Active AU2007275535B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US81781706P 2006-06-30 2006-06-30
US60/817,817 2006-06-30
PCT/US2007/070706 WO2008011234A2 (en) 2006-06-30 2007-06-08 Recombinant host for producing l-asparaginase ii

Publications (2)

Publication Number Publication Date
AU2007275535A1 AU2007275535A1 (en) 2008-01-24
AU2007275535B2 true AU2007275535B2 (en) 2012-08-16

Family

ID=38957454

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2007275535A Active AU2007275535B2 (en) 2006-06-30 2007-06-08 Recombinant host for producing L-asparaginase II

Country Status (17)

Country Link
US (2) US7807436B2 (https=)
EP (1) EP2046369B1 (https=)
JP (1) JP5308333B2 (https=)
KR (1) KR101408062B1 (https=)
CN (1) CN101484181B (https=)
AU (1) AU2007275535B2 (https=)
CA (1) CA2652718A1 (https=)
DK (1) DK2046369T3 (https=)
ES (1) ES2553329T3 (https=)
HU (1) HUE025738T2 (https=)
IL (1) IL195168A (https=)
MX (1) MX2009000284A (https=)
NZ (1) NZ572519A (https=)
PL (1) PL2046369T3 (https=)
PT (1) PT2046369E (https=)
TW (1) TWI427148B (https=)
WO (1) WO2008011234A2 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR102014000585B1 (pt) 2014-01-10 2021-01-12 Coppe/Ufrj-Instituto Alberto Luiz Coimbra De Pós-Graduação l-asparaginase recombinante de zymomonas
CN105802948B (zh) 2014-12-29 2020-06-09 江苏众红生物工程创药研究院有限公司 聚乙二醇定点修饰的门冬酰胺酶及其制备方法与应用
US10480014B2 (en) * 2015-06-15 2019-11-19 Ajou University Industry-Academic Cooperation Foundation Method for producing natural rubber by using recombinant microorganism
KR102783452B1 (ko) 2016-06-01 2025-03-19 세르비에 아이피 유케이 리미티드 폴리알킬렌 옥시드-아스파라기나제의 제형, 및 그의 제조 및 사용 방법
KR101837636B1 (ko) * 2016-06-14 2018-03-12 전남대학교산학협력단 코리네박테리움 재조합 균주를 이용한 아스파라기나제의 분비생산 방법
CN108795832B (zh) * 2017-04-26 2021-05-14 江苏恒瑞医药股份有限公司 一种内源l-门冬酰胺酶ii基因敲除的宿主菌、其制备方法及其应用
WO2019083794A1 (en) 2017-10-27 2019-05-02 Pfenex Inc. PROCESS FOR PRODUCING EAR ASPARAGINASE. RECOMBINED COLI
JP7784804B2 (ja) 2017-10-27 2025-12-12 フェネックス インク． 組み換えｅｒｗｉｎｉａアスパラギナーゼの製造のための方法
US11364223B2 (en) 2018-12-13 2022-06-21 Huyabio International, Llc Sulcardine administration for treatment of acute atrial fibrillation
US20220227805A1 (en) 2020-12-23 2022-07-21 Jazz Pharmaceuticals Ireland Ltd. Methods of purifying charge-shielded fusion proteins
CN114854729B (zh) * 2021-02-03 2025-09-02 重庆派金生物科技有限公司 定向化学偶联门冬酰胺酶突变体及其制备方法和应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5324844A (en) 1989-04-19 1994-06-28 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US5122614A (en) 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5919455A (en) 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US5615460A (en) * 1994-06-06 1997-04-01 The Procter & Gamble Company Female component for refastenable fastening device having regions of differential extensibility
US6180095B1 (en) 1997-12-17 2001-01-30 Enzon, Inc. Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents
US5965119A (en) 1997-12-30 1999-10-12 Enzon, Inc. Trialkyl-lock-facilitated polymeric prodrugs of amino-containing bioactive agents
US6958212B1 (en) 1999-02-01 2005-10-25 Eidgenossische Technische Hochschule Zurich Conjugate addition reactions for the controlled delivery of pharmaceutically active compounds
US7087229B2 (en) 2003-05-30 2006-08-08 Enzon Pharmaceuticals, Inc. Releasable polymeric conjugates based on aliphatic biodegradable linkers
US7122189B2 (en) 2002-08-13 2006-10-17 Enzon, Inc. Releasable polymeric conjugates based on aliphatic biodegradable linkers
CN100502944C (zh) * 2005-09-16 2009-06-24 北京双鹭药业股份有限公司 一种天门冬酰胺酶注射液、其制备方法及应用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Wang et al.,2001, vol 95, no 2, pages 93-101 *

Also Published As

Publication number Publication date
HUE025738T2 (en) 2016-04-28
KR20090033175A (ko) 2009-04-01
MX2009000284A (es) 2009-01-26
CN101484181A (zh) 2009-07-15
WO2008011234A2 (en) 2008-01-24
ES2553329T3 (es) 2015-12-07
TW200817518A (en) 2008-04-16
IL195168A (en) 2014-12-31
PT2046369E (pt) 2015-11-26
KR101408062B1 (ko) 2014-06-20
TWI427148B (zh) 2014-02-21
JP5308333B2 (ja) 2013-10-09
US7807436B2 (en) 2010-10-05
EP2046369A4 (en) 2010-04-21
US20080063632A1 (en) 2008-03-13
CA2652718A1 (en) 2008-01-24
NZ572519A (en) 2011-06-30
DK2046369T3 (en) 2015-11-30
CN101484181B (zh) 2012-12-26
AU2007275535A1 (en) 2008-01-24
JP2009542219A (ja) 2009-12-03
IL195168A0 (en) 2011-08-01
US20100273236A1 (en) 2010-10-28
EP2046369A2 (en) 2009-04-15
PL2046369T3 (pl) 2016-01-29
WO2008011234A3 (en) 2008-10-16
EP2046369B1 (en) 2015-08-12

Similar Documents

Publication Publication Date Title
AU2007275535B2 (en) Recombinant host for producing L-asparaginase II
JP4903891B2 (ja) シアノビリン変異体−ポリマー接合体
US5804183A (en) Arginine deminase derived from mycoplasma arthritidis and polymer conjugates containing the same
da Silva Freitas et al. Biochemical and biophysical characterization of lysozyme modified by PEGylation
US8663967B2 (en) Arginine deiminase mutant and preparation and application thereof
US11021690B2 (en) Mutant-type uricase, PEG modified mutant-type uricase, and application thereof
US20140363417A1 (en) Human Arginase and Pegylated Human Arginase and the UseThereof
US6635462B1 (en) Mutated form of arginine deiminase
CN101812438B (zh) 一种精氨酸脱亚氨酶突变体及其制备与应用
MX2008011495A (es) Toxina de clostridium botulinum mutada pegilada.
US20090047271A1 (en) Stable recombinant adenosine deaminase
JP2010500963A (ja) 安定化タンパク質
US20210340586A1 (en) Methods of Producing Full-Length Antibodies Using E. coli
US11060123B2 (en) Production of soluble recombinant protein without n-terminal methionine
RU2803949C1 (ru) Способ экспрессии белка crm197
KR880002319B1 (ko) 유전자 조환에 의한 사람알파 인터페론의 제조방법

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: DEFIANTE FARMACEUTICA, S.A.

Free format text: FORMER APPLICANT(S): ENZON PHARMACEUTICALS, INC.

PC1 Assignment before grant (sect. 113)

Owner name: SIGMA-TAU RARE DISEASES, S. A.

Free format text: FORMER APPLICANT(S): DEFIANTE FARMACEUTICA, S.A.

FGA Letters patent sealed or granted (standard patent)
HB Alteration of name in register

Owner name: SERVIER IP UK LIMITED

Free format text: FORMER NAME(S): SIGMA-TAU PHARMA LIMITED